Ranexa is a brand name of ranolazine, approved by the FDA in the following formulation(s):
RANEXA (ranolazine - tablet, extended release; oral)
Manufacturer: GILEAD
Approval date: January 27, 2006
Strength(s): 500MG
Manufacturer: GILEAD
Approval date: February 12, 2007
Strength(s): 1GM [RLD]
Has a generic version of Ranexa been approved?
No. There is currently no therapeutically equivalent version of Ranexa available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ranexa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for administering a sustained release ranolanolazine formulation
Patent 6,303,607
Issued: October 16, 2001
Inventor(s): Wolff; Andrew A. & Baker; Fiona & Langridge; John Richard
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,369,062
Issued: April 9, 2002
Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
Assignee(s): CV Therapeutics, Inc.
Syntex (USA) Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓✓
- May 27, 2019✓
- May 27, 2019
Methods for treating angina with ranolazine
Patent 6,479,496
Issued: November 12, 2002
Inventor(s): Andrew A.; Wolff
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,503,911
Issued: January 7, 2003
Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
Assignee(s): CV Therapeutics, Inc.
Syntex USA, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,525,057
Issued: February 25, 2003
Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,562,826
Issued: May 13, 2003
Inventor(s): Andrew A.; Wolff
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,617,328
Issued: September 9, 2003
Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
Assignee(s): CV Therapeutics, Inc
Syntex (USA), LLC
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,620,814
Issued: September 16, 2003
Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,852,724
Issued: February 8, 2005
Inventor(s): Wolff; Andrew A.
Assignee(s): CV Therapeutics, Inc.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Sustained release ranolazine formulations
Patent 6,864,258
Issued: March 8, 2005
Inventor(s): Wolff; Andrew A.
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Patent expiration dates:
- May 27, 2019✓
- May 27, 2019
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 27, 2011 - NEW CHEMICAL ENTITY
See also...
- Ranexa Consumer Information (Drugs.com)
- Ranexa Consumer Information (Wolters Kluwer)
- Ranexa Consumer Information (Cerner Multum)
- Ranexa Advanced Consumer Information (Micromedex)
- Ranexa AHFS DI Monographs (ASHP)
- Ranolazine Consumer Information (Wolters Kluwer)
- Ranolazine Consumer Information (Cerner Multum)
- Ranolazine Advanced Consumer Information (Micromedex)
- Ranolazine AHFS DI Monographs (ASHP)
No comments:
Post a Comment